RecruitingNot ApplicableNCT06990659

Outpatient Versus Inpatient Care Pathway for Intra-arterial Treatment of Primary Liver Cancer (CHOC)

CHOC - Implémentation et évaluation d'un Parcours de Soin Ambulatoire Pour Les Patients traités Par Voie Intra-artérielle d'un Cancer Primitif du Foie : Essai Multicentrique contrôlé randomisé


Sponsor

University Hospital, Angers

Enrollment

206 participants

Start Date

Dec 18, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Randomized multicentre trial comparing two care organisations (ambulatory vs conventional inpatient) for patients undergoing transarterial chemoembolization (TACE) or radioembolization (TARE) for primary liver cancer (Hepato Cellular Carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA)). Patients are followed for 7 months to assess patient satisfaction, safety and clinical outcomes. A qualitative implementation study and a medico-economic evaluation (cost analysis and 5-years budget impact analysis) are embedded to assess acceptability, adoption, feasability, and sustainability and to inform scaling.


Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing whether certain liver cancer patients can safely go home the same day after a minimally invasive procedure delivered through the arteries (called intra-arterial therapy), rather than staying overnight in the hospital. **You may be eligible if...** - You are 18 or older - You have been diagnosed with liver cancer (HCC) or bile duct cancer (iCCA) - You have not yet received intra-arterial treatment for this cancer - Your liver function is reasonably preserved (Child-Pugh score below B8) - You have signed informed consent **You may NOT be eligible if...** - You have significant blockage of the portal vein by the tumor - You have kidney failure (creatinine clearance below 30 mL/min) - You have a known allergy to contrast dye or chemotherapy agents - You are pregnant or breastfeeding - You are unable to arrange transport home or have someone with you the first night after discharge Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERAmbulatory care

Patients with Hepato cellular carcinoma (HCC) and Intrahepatic cholangiocarcinoma (iCCA) treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an outpatient basis: hospitalization in an outpatient unit, followed by systematic telephone and on-demand nursing follow-up for 48 hours for REH and 72 hours for CEH. A dedicated re-hospitalization circuit has also been set up in the event of complications.

OTHERConventional inpatient care

Patients with Hepato cellular carcinoma (HCC) and Intrahepatic cholangiocarcinoma treated by chemo-embolization (CEH) or radioembolization (REH) are managed on an inpatient basis: conventional hospitalization.


Locations(14)

University hospital of Amiens

Amiens, France

University hospital of Angers

Angers, France

University hospital of Besançon

Besançon, France

Hospital of Avicennes (AP-HP)

Bobigny, France

University hospital of Brest

Brest, France

Hospital of Beaujon (AP-HP)

Clichy, France

Hospital of Vendée

La Roche-sur-Yon, France

University hospital of Grenoble-Alpes

La Tronche, France

University hospital of Montpellier

Montpellier, France

University hospital of Nice

Nice, France

Hospital of Pitié-Salpétrière (AP-HP)

Paris, France

Hospital of Cochin (AP-HP)

Paris, France

Univesity hospital of Bordeaux

Pessac, France

Institut Gustave Roussy (IGR)

Villejuif, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06990659


Related Trials